Mary Newman is VP at Audentes Therapeutics, Inc. (BOLD). They have made 4 open-market trades across 1 company since 2017, most recently 2018-11-15.
CIK 0001679132
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BOLD | 660 | $2K |
Shares reported on the most recent Form 4, priced at the 2018-11-16 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.